Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation
Schizophrenia Bulletin · 08.09.2025 · 51 (5) · 1193-1205
DOI: 10.1093/schbul/sbae205 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 09.12.2024. Verfasst von Aoife Carolan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Saint John of God Hospital, Dublin, A94 FH92, Ireland. Hauptthemen laut MEDLINE: Antipsychotic Agents, Metformin, Weight Gain, Practice Guidelines as Topic. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Research Board.
Abstract (Originalsprache)
Background
Overweight and obesity are highly prevalent in people with severe mental illness (SMI). Antipsychotic-induced weight gain (AIWG) is one of the most commonly reported and distressing side effects of treatment and people living with SMI place a high value on the avoidance of this side effect. Metformin is the most effective pharmacological intervention studied for the prevention of AIWG yet clear guidelines are lacking and evidence has not translated into practice. The aim of this research was to develop a guideline for the use of metformin for the prevention of AIWG. Study Design The appraisal of guidelines for research and evaluation II instrument (AGREE II) was followed for guideline development. Literature was reviewed to address key health questions. The certainty of evidence was evaluated using GRADE methodology and an evidence-to-decision framework informed the strength of the recommendations. A consensus meeting was held where the algorithm and strength of recommendations were agreed. An independent external review was conducted involving experts in the field, including patient and public partners. Study Results Metformin is the only pharmacological agent that has demonstrated efficacy for preventing AIWG. Co-commencement with antipsychotic medicines can reduce the extent of weight gain by 4.03 kg (95% CI −5.78 kg to −2.28 kg) compared to controls. A guideline for the use of metformin for the prevention of AIWG was developed with specific recommendations for co-commencement of metformin at initiation with an antipsychotic or commencement if certain criteria are present. Core recommendations were graded as strong by consensus agreement.
Conclusions
This is the first published evidence-based guideline using the AGREE II framework and GRADE methods for the use of metformin to prevent AIWG incorporating recommendations for co-commencement. Implementation and evaluation of the guideline will be supported by a shared decision-making package and assessment of barriers and facilitators to implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Saint John of God Hospital, Dublin, A94 FH92, Ireland.
- School of Pharmacy and Biomolecular Science, Royal College of Surgeons, D02 V951, Dublin, Ireland.
- Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, ON, M5T 1R8, Canada.
- Institute of Medical Sciences, University of Toronto, Toronto, ON, M5 S1A8, Canada.
- Department of Psychiatry, University of Toronto, Toronto, ON, M5T1R8, Canada.
- Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, M5G 2C4, Canada.
ORCID-Profile: Aoife Carolan, Amir Krivoy, Stefan Leucht, Michael J Norton, Toby Pillinger, Dan Siskind, Brian O'Donoghue
Förderung
- Health Research Board
Zitieren
APA
Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., Hahn, M. K., Krivoy, A., Lally, J., Leucht, S., Lyne, J., McCutcheon, R. A., Norton, M. J., O'Connor, K., Perry, B. I., Pillinger, T., Shiers, D., Siskind, D., Thompson, A., …, & O'Donoghue, B. (2025). Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin, 51(5), 1193-1205. https://doi.org/10.1093/schbul/sbae205
Vancouver
Carolan A, Hynes-Ryan C, Agarwal SM, Bourke R, Cullen W, Gaughran F, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193-1205. doi:10.1093/schbul/sbae205
BibTeX
@article{Carolan2025,
author = {Carolan, Aoife and Hynes-Ryan, Caroline and Agarwal, Sri Mahavir and Bourke, Rita and Cullen, Walter and Gaughran, Fiona and Hahn, Margaret K and Krivoy, Amir and Lally, John and Leucht, Stefan and Lyne, John and McCutcheon, Robert A and Norton, Michael J and O'Connor, Karen and Perry, Benjamin I and Pillinger, Toby and Shiers, David and Siskind, Dan and Thompson, Andrew and O'Shea, Donal and Keating, Dolores and O'Donoghue, Brian},
title = {Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation},
journal = {Schizophrenia Bulletin},
year = {2025},
volume = {51},
number = {5},
pages = {1193--1205},
doi = {10.1093/schbul/sbae205}
}
EUVIMED